Novartis Brings “Disruptive Innovation” To Clinical Trials
Having reinvigorated its model for early R&D, the company is looking to re-envision the clinical trial process, with initiatives aimed at improving patient selection based on molecular information, clinical trial recruitment and monitoring. A partnership with Walgreens aims to move trials out of tertiary care centers and into pharmacies.
You may also be interested in...
‘Decentralized Clinical Trials 2.0’ On The Horizon
The remarkable shift towards decentralized clinical trials in the last three years is a testament to how this patient-centric approach of doing research has the potential to solve multiple issues such as time, cost and low participation rates. In this first segment of a two-part article, the Pink Sheet looks at how innovation in this sector has just begun and we can expect more action ahead.
Novartis Counting On Depth Of Insight To Continue Success In Oncology
Its cancer pipeline planned with combinations in mind, the world’s second largest oncology company is positioned to ride the crest of the new wave in cancer drug development. Novartis is also paving new ground with quality of life research, an area of growing importance for oncology.
An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
With almost 40 novel agents already pending at FDA, 2013 looks like a good bet to repeat the strong NME and novel biologic approval counts of 2012 and 2011. Big pharma and big markets dominate the 2013 slate so far, especially with diabetes, respiratory and central nervous system candidates.